Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump’s Initiative to Encourage Pharmaceutical Manufacturing in United States

Rhea-AI Summary

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has announced the launch of Tevogen Generics, a new initiative aimed at domestic manufacturing of unbranded pharmaceuticals and APIs. This effort aligns with President Trump's recent tariff-related statements and national focus on pharmaceutical affordability.

The company has appointed Sadiq Khan, MBA, the current Chief Commercial Officer, as Interim Head of this new venture. Tevogen Generics becomes the company's third strategic pillar, alongside:

• Tevogen Bio - specialty immunotherapy biotech focusing on off-the-shelf, precision T cell therapies
• Tevogen.AI - utilizing artificial intelligence for drug discovery and healthcare delivery optimization
• Tevogen Generics - focused on making essential medicines accessible

Positive

• Strategic expansion into generic drug manufacturing market
• Alignment with government initiatives supporting domestic pharmaceutical production
• Diversification of business model with three distinct strategic pillars

Negative

• Additional capital needs mentioned for business plan execution
• Risks associated with new market entry and operational expansion
• Competitive challenges in generic pharmaceutical market

Insights

Pharmaceutical Industry Analyst

Tevogen's announcement of Tevogen Generics represents a strategic expansion into domestic generic drug manufacturing, positioning the company to potentially benefit from changing political attitudes toward pharmaceutical manufacturing independence.

This initiative directly aligns with President Trump's recent tariff-related statements and broader discussions around pharmaceutical supply chain security. By appointing CCO Sadiq Khan as interim head of this new division, Tevogen is leveraging existing executive talent while signaling organizational commitment to this new direction.

The announcement establishes Tevogen Generics as the company's third strategic pillar alongside its specialty immunotherapy biotech (Tevogen Bio) and artificial intelligence division (Tevogen.AI). This diversification strategy spans cutting-edge biotechnology, artificial intelligence, and now more conventional pharmaceutical manufacturing.

However, the announcement lacks critical implementation details – no information on capital investment, manufacturing facilities, product pipeline, regulatory strategy, or timeline is provided. Without these specifics, the immediate business impact remains unclear. The press release serves primarily as a statement of strategic intent rather than a detailed business plan.

For a company primarily focused on specialty immunotherapies and AI applications, this expansion into generics manufacturing represents a significant operational pivot requiring different expertise, regulatory approaches, and capital allocation. The success of this initiative will depend on Tevogen's ability to develop or acquire manufacturing capabilities while maintaining focus on its existing business segments.

WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announces its newest effort: Tevogen Generics. This effort is in response to the growing national focus on pharmaceutical affordability and coincides with the recent tariff-related statements from President Donald Trump.

To lead the launch of Tevogen Generics, the Company has expended responsibilities of its Chief Commercial Officer, Sadiq Khan, MBA, to include Interim Head of this new effort. A seasoned pharmaceutical executive, Khan brings decades of experience in global commercial operations and alliances.

"This initiative seeks to expedite the domestic manufacturing of unbranded pharmaceuticals and APIs, thereby enhancing national self-reliance in the supply of vital, life-saving treatments," commented Sadiq Khan.

Tevogen Generics now stands as the third strategic pillar of Tevogen Bio Holdings Inc., joining:

1. Tevogen Bio – specialty immunotherapy biotech pioneering off-the-shelf, precision T cell therapies.
2. Tevogen.AI – leveraging artificial intelligence to accelerate drug discovery and streamline healthcare delivery.
3. Tevogen Generics – dedicated to making high-quality, essential medicines accessible to all.
   

Further updates will be provided as Tevogen Generics progresses in its development and implementation.

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer; Tevogen’s plans to expand its efforts in artificial intelligence; Tevogen’s ability to develop additional product candidates; Tevogen’s use of funds from the grant; and the potential receipt of additional future grants. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701

Communications@Tevogen.com

FAQ

What is the purpose of Tevogen's new generics division announced in April 2025?

Tevogen Generics aims to manufacture unbranded pharmaceuticals and APIs domestically, supporting pharmaceutical affordability and national self-reliance in vital medicine supply.

Who will lead Tevogen's new generics initiative (TVGNW)?

Sadiq Khan, MBA, the company's Chief Commercial Officer, will serve as Interim Head of Tevogen Generics.

What are the three strategic pillars of Tevogen following the April 2025 announcement?

The three pillars are Tevogen Bio (immunotherapy), Tevogen.AI (artificial intelligence), and Tevogen Generics (affordable medicines).

How does Tevogen's new generics division align with government initiatives?

The initiative aligns with President Trump's tariff-related statements and the national focus on pharmaceutical affordability and domestic manufacturing.